Blinding in randomised trials: hiding who got what. (Q52937785)

9 May 2018

title

Blinding in randomised trials: hiding who got what. (English)

1 reference

9 May 2018

2

David A Grimes

1 reference

9 May 2018

Kenneth F Schulz

1

1 reference

9 May 2018

language of work or name

English

0 references

publication date

1 February 2002

1 reference

9 May 2018

published in

The Lancet

1 reference

9 May 2018

volume

359

1 reference

9 May 2018

page(s)

696-700

1 reference

9 May 2018

issue

9307

1 reference

9 May 2018

Intentional ignorance: a history of blind assessment and placebo controls in medicine.

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2907816-9

7 January 2021

Physician interpretations and textbook definitions of blinding terminology in randomized controlled trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2907816-9

7 January 2021

The Landscape and Lexicon of Blinding in Randomized Trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2907816-9

7 January 2021

Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2907816-9

7 January 2021

Assessing the quality of randomization from reports of controlled trials published in obstetrics and gynecology journals

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2907816-9

7 January 2021

What is the prior probability of a proposed new treatment being superior to established treatments?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2907816-9

7 January 2021

Effects of suggestion and conditioning on the action of chemical agents in human subjects; the pharmacology of placebos

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2907816-9

7 January 2021

The impact of blinding on the results of a randomized, placebo-controlled multiple sclerosis clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2907816-9

7 January 2021

Statistics notes: blinding in clinical trials and other studies

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2907816-9

7 January 2021

The controlled clinical trial: Theory and practice

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2907816-9

7 January 2021

Randomized controlled trials in cystic fibrosis (1966-1997) categorized by time, design, and intervention

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2907816-9

7 January 2021

Methodology and overt and hidden bias in reports of 196 double-blind trials of nonsteroidal antiinflammatory drugs in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2907816-9

7 January 2021

How well are randomized controlled trials reported in the dermatology literature?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2907816-9

7 January 2021

Reporting on methods in clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2907816-9

7 January 2021

Blinding and exclusions after allocation in randomised controlled trials: survey of published parallel group trials in obstetrics and gynaecology

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2907816-9

7 January 2021

Empirical evidence of bias in infertility research: overestimation of treatment effect in crossover trials using pregnancy as the outcome measure.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2907816-9

7 January 2021

Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2907816-9

7 January 2021

The revised CONSORT statement for reporting randomized trials: explanation and elaboration

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2907816-9

7 January 2021

The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2907816-9

7 January 2021

Low-dose dopamine in patients with early renal dysfunction: a placebo-controlled randomised trial. Australian and New Zealand Intensive Care Society (ANZICS) Clinical Trials Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2907816-9

7 January 2021

Effect of sibutramine on weight maintenance after weight loss: a randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2907816-9

7 January 2021

A controlled trial of nonoxynol 9 film to reduce male-to-female transmission of sexually transmitted diseases

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2907816-9

7 January 2021

Preventing IUCD-related pelvic infection: the efficacy of prophylactic doxycycline at insertion.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2907816-9

7 January 2021

Validity of clinical trials of antidepressants

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2907816-9

7 January 2021

A Randomized Trial of Aspirin and Sulfinpyrazone in Threatened Stroke

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2907816-9

7 January 2021

An open prospective randomised trial to reduce the pain of blood glucose testing: ear versus thumb.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2907816-9

7 January 2021

10.1016/S0140-6736(02)07816-9

Identifiers

DOI

1 reference

9 May 2018

PubMed ID

11879884

1 reference

9 May 2018